{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019016","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.410240+00:00","generated_at":"2026-06-08T04:30:02.194311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Armata Q3 loss from ops $(10.3)M; cash $24M; AP-SA02 and AP-PA02 enrollment accelerating","bullets":["Grant revenue $1.2M (vs $1.3M); R&D $8.0M (vs $8.4M); G&A $3.6M (vs $1.6M) due to one-time financing costs.","Loss from operations widened to $(10.3)M from $(8.6)M YoY.","Cash $24.0M as of Sept 30 vs $14.9M Dec 31, 2022; $25M credit agreement with Innoviva signed July 2023.","Phase 2a diSArm (AP-SA02) and Phase 2 Tailwind (AP-PA02) enrollment accelerating; expects Phase 2 diSArm completion in 2024.","Shares outstanding ~36.1M as of Nov 14, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019016","json":"https://secwatch.observer/filing/0001558370-23-019016.json","markdown":"https://secwatch.observer/filing/0001558370-23-019016.md","text":"https://secwatch.observer/filing/0001558370-23-019016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/0001558370-23-019016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/armp-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:30:02.194311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cb98a7a7543339d34279c50a1b70453c0165f10","claim":"Armata Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue grant revenue of approximately $1.2 million.","evidence_excerpt":"through the remainder of the year and into 2024,” Dr. Birx concluded. Third Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.2 million for the three months ended September 30, 2023, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/0001558370-23-019016-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"grant revenue of approximately $1.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}